We produce institutional quality equity research on small/midcap healthcare and life sciences companies, making it available to all investors wherever they are based. Our goal is to bring exciting investment ideas to investors, and to assist companies in achieving their objectives.
10
Research Clients
285
Reports published
10k+
Readers in database
Differentiated #insulin formulations AT247 & AT278 are central to @arecor_plc's attractive & low risk #diabetes franchise. Continued clinical progress shld give more insights into profiles, positioning, & partnering opps. #Arecor
For more on #AREC see: https://www.trinitydelta.org/companies/arecor-therapeutics/
AVA3996 is @avacta's 2nd pre|CISION pro-drug development candidate. A Velcade analogue pro-drug designed to offer potentially improved safety, reduced DLTs, w/ possible applicability to solid tumours. IND/CTA filing targeted H123; Phase I start H223. #AVCT https://avacta.com/avacta-selects-second-precisiontm-pro-drug-candidate-for-development/
New paper indicates good correlation b/w @Parsortix's #LiquidBiopsy & tumour biopsy in metastatic #BreastCancer. FDA clearance pending; submissions for US & UK clinical lab accreditation underway; ovarian study data now expected H122.
For more on #AGL see: https://www.trinitydelta.org/companies/angle/
H122 trading statement ahead of #AllergyTherapeutics’ results on March 3 confirms solid trading in challenging environment (-5% CER, +3% LFL) & cash to fund Grass MATA MPL & VLP #Peanut #allergy studies starting later in 2022.
For more on $AGY see: https://www.trinitydelta.org/companies/allergy-therapeutics/
Admirable progress on @NexstimOyj's 2021 strategic goals, with a >200 MDD pt registry, encouraging pilot data in #depression (more to come in H222) & 1st partners (Recuror, PNC). FY22 results report Feb 28. For more on #NXTHM see: https://www.trinitydelta.org/companies/nexstim/
ICYMI: sales of @avacta's AffiDx #COVID #LFT halted due to variable #omicron detection at low viral loads. Uncertain timelines depend on development progress & regulatory requirements for the new LFT. For more on #AVCT see: https://www.trinitydelta.org/companies/avacta/
Please sign up here to be added to our distribution database
';